Association of Hla Class Ii Alleles With Disease Severity and Treatment Response in Iranian Patients With Myasthenia Gravis

Association of Hla Class Ii Alleles With Disease Severity and Treatment Response in Iranian Patients With Myasthenia Gravis Publisher Pubmed

Sinaei F¹ ; Fatehi F¹ ; Oveis Gharan S^{1, 2} ; Ehsan S¹ ; Kamali K³ ; Amirzargar A^{4, 5} ; Mahmoudi M⁶ ; Vaghefifar A¹ ; Nafissi S¹

Show Affiliations

1. Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
2. Rush Alzheimer Disease Center, Rush University Medical Center, Chicago, IL, United States
3. Department of Public Health, School of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran
4. Molecular Immunology Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
6. Rheumatology Research Center (RRC), Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Neuromuscular Diseases Published:2021

Abstract

Myasthenia gravis is an autoimmune neuromuscular disease with a multifactorial etiology. A major part of the genetic susceptibility belongs to the HLA encoding genes. In this study, we investigated the role of HLA class II polymorphism in disease severity, and treatment response. In our 146 patients, 15 DRB1, 7 DQA1, and 9 DQB1 alleles, and 19 haplotypes were found. Adjusted p-values did not show any significant associations between these loci, disease severity and treatment outcome. Further studies in different populations with a larger number of patients are needed to determine the exact contribution of HLA class II alleles to MG prognosis. © 2021-IOS Press. All rights reserved.

Experts (# of related papers)

Farzad Fatehi (1)

Shahriar Nafissi (1)

Style	Citing Format
MLA	Sinaei F, et al.. "Association of Hla Class Ii Alleles With Disease Severity and Treatment Response in Iranian Patients With Myasthenia Gravis." Journal of Neuromuscular Diseases, vol. 8, no. 5, 2021, pp. 827-829.
APA	Sinaei F, Fatehi F, Oveis Gharan S, Ehsan S, Kamali K, Amirzargar A, Mahmoudi M, Vaghefifar A, Nafissi S (2021). Association of Hla Class Ii Alleles With Disease Severity and Treatment Response in Iranian Patients With Myasthenia Gravis. Journal of Neuromuscular Diseases, 8(5), 827-829.
Chicago	Sinaei F, Fatehi F, Oveis Gharan S, Ehsan S, Kamali K, Amirzargar A, Mahmoudi M, Vaghefifar A, Nafissi S. "Association of Hla Class Ii Alleles With Disease Severity and Treatment Response in Iranian Patients With Myasthenia Gravis." Journal of Neuromuscular Diseases 8, no. 5 (2021): 827-829.
Harvard	Sinaei F et al. (2021) 'Association of Hla Class Ii Alleles With Disease Severity and Treatment Response in Iranian Patients With Myasthenia Gravis', Journal of Neuromuscular Diseases, 8(5), pp. 827-829.
Vancouver	Sinaei F, Fatehi F, Oveis Gharan S, Ehsan S, Kamali K, Amirzargar A, et al.. Association of Hla Class Ii Alleles With Disease Severity and Treatment Response in Iranian Patients With Myasthenia Gravis. Journal of Neuromuscular Diseases. 2021;8(5):827-829.
BibTex	@article{ author = {Sinaei F and Fatehi F and Oveis Gharan S and Ehsan S and Kamali K and Amirzargar A and Mahmoudi M and Vaghefifar A and Nafissi S}, title = {Association of Hla Class Ii Alleles With Disease Severity and Treatment Response in Iranian Patients With Myasthenia Gravis}, journal = {Journal of Neuromuscular Diseases}, volume = {8}, number = {5}, pages = {827-829}, year = {2021} }
RIS	TY - JOUR AU - Sinaei F AU - Fatehi F AU - Oveis Gharan S AU - Ehsan S AU - Kamali K AU - Amirzargar A AU - Mahmoudi M AU - Vaghefifar A AU - Nafissi S TI - Association of Hla Class Ii Alleles With Disease Severity and Treatment Response in Iranian Patients With Myasthenia Gravis JO - Journal of Neuromuscular Diseases VL - 8 IS - 5 SP - 827 EP - 829 PY - 2021 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract